# Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

> **NCT04544098** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors

## Interventions

- **DRUG:** 177Lu-DOTATATE

## Key facts

- **NCT ID:** NCT04544098
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-02
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04544098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04544098, "Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT04544098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*